**GENERIC SPECIALS - DEEP DISCOUNTS **
"Weekly Generics Campaign"
LOOK for DEEP Discounts with APCI's Weekly Generics Campaign!
Regular ordering through McKesson - discount price will be in place during campaign period.
Items on the Generics Campaign this week:
Effective for orders placed 3/19/15 – 3/25/15
ITEM# |
NDC |
DESC |
TOP 250 |
CAMPAIGN ORDER DATES |
CAMPAIGN INVOICE DATES |
DISC % |
1395839 |
68382012305 |
AMLODIPINE
10MG 500 |
N |
3/26/15-4/01/15 |
3/27/15-4/02/15 |
30% |
1803170 |
00093423401 |
BUMETAN 2MG
100 |
N |
3/26/15-4/01/15 |
3/27/15-4/02/15 |
30% |
1705755 |
55111053201 |
DIVALP SPRNK 125MG DR100 |
N |
3/26/15-4/01/15 |
3/27/15-4/02/15 |
30% |
2237105 |
00591272060 |
METFORM ER 1000MG 60 |
Y |
3/26/15-4/01/15 |
3/27/15-4/02/15 |
30% |
1417088 |
00555083302 |
WARFARIN 5MG
100 |
Y |
3/26/15-4/01/15 |
3/27/15-4/02/15 |
30% |
(Limited
supply available of some items, watch for items to run again on future
campaigns)
Watch for these
Items on Generics Campaign NEXT week:
ITEM# |
NDC |
DESC |
TOP 250 |
CAMPAIGN DATES |
INVOICE DATES |
DISC % |
2208734 |
00093517355 |
NIFEDIC XL ER 60MG 300 |
N |
4/02/15-4/08/15 |
4/03/15-4/09/15 |
30% |
1407683 |
555083202 |
WARFARIN 2.5MG 100 |
N |
4/02/15-4/08/15 |
4/03/15-4/09/15 |
30% |
1372002 |
60505082901 |
FLUTICAS SP 50MCG 16GM |
Y |
4/02/15-4/08/15 |
4/03/15-4/09/15 |
30% |
1139781 |
781502207 |
METHYLPRED 4MG 21 |
Y |
4/02/15-4/08/15 |
4/03/15-4/09/15 |
30% |
2026979 |
55111053405 |
DIVALPROEX ER 5OOMG 500 |
Y |
4/02/15-4/08/15 |
4/03/15-4/09/15 |
30% |
Thank you for your valuable feedback:
Campaign item is out of stock at my DC – We do everything we can to ensure that inventory is in place when making the decision to add items to the campaign. However, we plan a few weeks out and inventory at times may be depleted at one or two of our McKesson servicing DC’s by the time the campaign begins. You will receive substituted products if available with A slot pricing protection. If a substitute isn’t available, don’t worry; we will run these items again in a few weeks to give all of our members a chance to take advantage of these great prices!
Check out a full list of Custom Discounted Items our website weekly - updated every Monday!
https://www.apcinet.com/AboutUs/Services/VendorContracting/APCIDiscountedGenerics/tabid/535/Default.aspx
|
NEWS YOU CAN USE
|
FDA seeks input on product-specific recommendations to assist and facilitate generic drug development
03/17/2015
FDA has published 60 product-specific recommendations describing the Agency’s current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference-listed drugs.
FDA is always seeking feedback and considers all comments to the docket before it begins work on the final version of a product-specific bioequivalence guidance.
As of 2015, the Agency provides quarterly notification of these recommendations for public consideration.
FDA Drug Shortages
- Ammonium Chloride Injection
(Updated - Currently in Shortage)
- Bupivacaine Hydrochloride (Marcaine, Sensorcaine)
Injection (Updated - Currently in Shortage)
- Dextrose 5% Injection Bags
(Updated - Currently in Shortage)
- Epinephrine Injection
(Updated - Currently in Shortage)
- Haloperidol Lactate Injection
(Updated - Currently in Shortage)
- Ketorolac Tromethamine Injection
(Updated - Currently in Shortage)
- Magnesium Sulfate Injection
(Updated - Currently in Shortage)
- Morphine Sulfate (Astramorph PF, Duramorph,
Infumorph) Injection (Preservative Free)
(Updated - Currently in Shortage)
- Multi-Vitamin Infusion (Adult and Pediatric)
(Updated - Currently in Shortage)
- Nalbuphine Hydrochloride (Nubain) Injection
(Updated - Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection
(Updated - Currently in Shortage)
- Potassium Chloride Injection
(Updated - Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags
(Updated - Currently in Shortage)
- Vancomycin Hydrochloride for Injection, USP
(Updated - Currently in Shortage)
Download the Drug Shortages Mobile Application
New and Generic Drug Approvals
Drug Name |
Active Ingredient |
Dosage Form/Route |
Sponsor |
Submission Type |
Actoplus Met Xr |
metformin hydrochloride; pioglitazone hydrochloride |
Tablet, Extended Release;Oral |
Takeda Pharms Usa |
Manufacturing Change or
Addition |
Benzamycin Pak |
benzoyl peroxide; erythromycin |
Gel;Topical |
Valeant Luxembourg |
Manufacturing Change or
Addition |
Chlorhexidine Gluconate |
chlorhexidine gluconate |
Cloth;Topical |
Sage Prods |
Manufacturing Change or
Addition |
Contrave |
bupropion hydrochloride; naltrexone hydrochloride |
Tablet, Extended Release;Oral |
Takeda Pharms Usa |
Manufacturing Change or
Addition |
Depocyt |
cytarabine |
Injectable, Liposomal;Injection |
Pacira Pharms Inc |
Manufacturing Change or
Addition |
Invanz |
ertapenem sodium |
Injectable;Intramuscular, Iv (Infusion) |
Merck Sharp Dohme |
Manufacturing Change or
Addition |
Mephyton |
phytonadione |
Tablet;Oral |
Valeant Pharms |
Manufacturing Change or
Addition |
Tamiflu |
oseltamivir phosphate |
For Suspension;Oral |
Roche |
Manufacturing Change or
Addition |
Viibryd |
vilazodone hydrochloride |
Tablet;Oral |
Forest Labs Inc |
Efficacy Supplement with
Clinical Data to Support |
Zecuity |
sumatriptan succinate |
System;Iontophoresis |
Teva Branded Pharm |
Manufacturing Change or
Addition |
Zinacef |
cefuroxime sodium |
Injectable;Injection |
Covis Injectables |
Manufacturing Change or
Addition |
Zinacef |
cefuroxime sodium |
Injectable;Intramuscular, Intravenous |
Covis Injectables |
Manufacturing Change or
Addition |
Drug Information Update- FDA approves Cholbam to treat rare bile acid synthesis disorders
03/18/2015
The U.S. Food and Drug Administration approved Cholbam (cholic acid)
capsules, the first FDA approved treatment for pediatric and adult patients
with bile acid synthesis disorders due to single enzyme defects, and for
patients with peroxisomal disorders (including Zellweger spectrum disorders). Patients with these
rare, genetic, metabolic conditions exhibit manifestations of liver
disease, steatorrhea (presence of fat in the
stool) and complications from decreased fat-soluble vitamin absorption.
Individuals with these rare disorders lack the enzymes
needed to synthesize cholic acid, a primary bile
acid normally produced in the liver from cholesterol. The absence of cholic acid in these patients leads to reduced bile flow, accumulation of potentially toxic bile acid
intermediates in the liver (cholestasis), and malabsorption of fats and
fat-soluble vitamins in the diet. If untreated, patients fail to grow and
can develop life-threatening liver injury.
Cholbam is
approved as an oral treatment for children aged three weeks and older, and
adults. The manufacturer of Cholbam was granted a
rare pediatric disease priority review voucher–a provision that
encourages development of new drugs and biologics for the prevention and
treatment of rare pediatric diseases.
For more information, please visit: Cholbam.
McKesson OneStop Generics®
Price Assurance Promotion – Price Alert
March 20, 2015
Please make note of the following item eligible for the Price Assurance
Promotion:
ITEM NUMBER |
NDC |
DESCRIPTION |
START DATE |
END DATE |
TOP MOVERS |
1295039 |
43478027015 |
HYDROCORT BU CRM 0.1%ROUS15GM |
3/21/2015 |
4/20/2015 |
|
McKesson has been notified of 1 product family representing 1 item that
increases in price on March 21, 2015. A customer's purchase
of these items will be covered by the Price Assurance Promotion for 30
days following the price assurance start date.
Customers will receive price assurance payments on purchases
of eligible product during the 30-day price assurance period, up to a maximum
quantity determined by their purchase history. Price assurance will be provided
on the difference between the new invoice price and the invoice price before
the invoice price increase, multiplied by the eligible quantity.
For more information, please visit the OneStop Generics homepage on McKesson Connect.
Note: The percentage increase in the invoice price may vary
from the percentage increase in the WAC price
Launch of generic Epivir®
On Thursday, March 19, Silarx Pharmaceuticals Inc. launched the generic equivalent
of Epivir® oral solution (lamivudine). The Silarx item
will be added to the OneStop program in the primary position with visibility in
McKesson Connect on Tuesday, March 24. Estimated brand sales of Epivir®
oral solution are approximately $4M.
Brand Item:
Item # |
NDC |
Description |
1603125 |
54838056670 |
LAMIVUD O/S 10MG/ML SILA 240ML |
There will be no ASAP or ASAP Plus for this launch.
Product Launch Information - OneStop Add |
Bx Name |
Epivir |
Bx Supplier |
ViiV Healthcare |
Generic Name |
lamivudine |
Generic Description |
lamivudine oral solution, 10mg/ml 240ml |
Therapeutic Class/Indication |
Indicated as part of antiretroviral combination therapy
for the treatment of Human Immunodeficiency Virus (HIV) infected adults and
children. |
FDA Approval Date |
10/31/2014 |
Launch Reason |
FDA Approval |
Launch Exclusivity |
Yes |
Number of Players |
1 |
US Brand Sales |
$4M |
To order, please use the following item number:
Item # |
Supplier Name |
NDC |
Description |
OS ADD |
3431566 |
SILARX PHARMACEUTICALS INC |
54838056670 |
LAMIVUD O/S 10MG/ML SILA 240ML |
03/24/2015 |
For questions please contact ISManagement@McKesson.com.
APCI Approved Vendors